Ascites Pipeline Summary

DelveInsight’s, “Ascites - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ascites pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ascites: Understanding

Ascites: Overview

Ascites is the pathological accumulation of fluid within the peritoneal cavity and is most commonly associated with liver disease, particularly cirrhosis, although it can also occur due to cardiac, renal, pancreatic, infectious, and malignant conditions. In patients with cirrhosis, the development of ascites often indicates progression from compensated to decompensated liver disease and is associated with complications such as spontaneous bacterial peritonitis and hepatorenal syndrome.

Cirrhosis is the predominant cause of ascites, accounting for approximately 80% of cases in the United States, with alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic viral hepatitis being major underlying causes. Other causes include peritoneal malignancy, congestive heart failure, nephrotic syndrome, tuberculosis, pancreatitis, pancreatic duct disruption, and lymphatic disorders causing chylous ascites. In cirrhotic ascites, portal hypertension is the initiating event, resulting in increased nitric oxide production and splanchnic arterial vasodilation. This reduces the effective arterial blood volume and activates the renin-angiotensin-aldosterone system, sympathetic nervous system, and arginine vasopressin, promoting renal sodium and water retention. Increased splanchnic capillary pressure and lymph production further contribute to fluid accumulation in the peritoneal cavity.

Diagnosis involves clinical examination, imaging, and analysis of ascitic fluid. Patients commonly present with progressive abdominal distension, discomfort, weight gain, early satiety, and dyspnea, with physical findings such as shifting dullness and a fluid wave. Diagnostic abdominal paracentesis is the key initial investigation, with ascitic fluid analyzed for cell count, culture, cytology, albumin, and other parameters. The serum-ascites albumin gradient (SAAG) helps determine the underlying cause: a SAAG ?1.1 g/dL suggests portal hypertension, whereas a SAAG <1.1 g/dL suggests non-portal hypertensive causes. Ultrasound is highly sensitive for detecting ascitic fluid, while CT can help identify underlying masses or other pathology.

Management is directed toward the underlying cause and reduction of fluid accumulation while maintaining adequate intravascular volume. For cirrhotic ascites, dietary sodium restriction and diuretics, particularly spironolactone with or without furosemide, are first-line treatments. Patients with tense or refractory ascites may require therapeutic large-volume paracentesis, generally accompanied by albumin replacement when large volumes are removed. Transjugular intrahepatic portosystemic shunt (TIPS) may be considered for carefully selected patients with refractory ascites, while liver transplantation should be evaluated in appropriate patients with advanced cirrhosis.

"Ascites- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ascites pipeline landscape is provided which includes the disease overview and Ascites treatment guidelines. The assessment part of the report embraces, in depth Ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Ascites R&D. The therapies under development are focused on novel approaches to treat/improve Ascites.

Ascites Emerging Drugs Chapters

This segment of the Ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ascites Emerging Drugs

• M701: YZY Biopharma

M701 is a first-in-class biologic which simultaneously targets EpCAM and CD3 to redirect and activate T cells against EpCAM-positive tumor cells. This drug is developed by YZY Biopharma using its proprietary YBODY® asymmetric bispecific antibody platform. It is being developed for the treatment of malignant ascites and malignant pleural effusion associated with EpCAM-expressing cancers, and is currently undergoing Phase III clinical evaluation for Ascites.

Further product details are provided in the report……..

Ascites: Therapeutic Assessment

This segment of the report provides insights about the different Ascites drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Ascites

There are approx. 5+ key companies which are developing the therapies Ascites. The companies which have their Ascites drug candidates in the most advanced stage, i.e. Phase III include, YZY Biopharma and others.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ascites: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ascites therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ascites drugs.

Ascites Report Insights

• Ascites Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ascites Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ascites drugs?
• How many Ascites drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ascites?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ascites therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ascites and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• YZY Biopharma
• WestVac Biopharma Co., Ltd.

Key Products

• M701
• WSK-IM02